Unknown

Dataset Information

0

Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells.

ABSTRACT: High activation of DNA damage response is implicated in cisplatin (CDDP) resistance which presents as a serious obstacle for bladder cancer treatment. Cdc6 plays an important role in the malignant progression of tumor. Here, we reported that Cdc6 expression is up-regulated in bladder cancer tissues and is positively correlated to high tumor grade. Cdc6 depletion can attenuate the malignant properties of bladder cancer cells, including DNA replication, migration and invasion. Furthermore, higher levels of chromatin-binding Cdc6 and ATR were detected in CDDP-resistant bladder cancer cells than in the parent bladder cancer cells. Intriguingly, down-regulation of Cdc6 can enhance sensitivity to CDDP both in bladder cancer cells and CDDP-resistant bladder cancer cells. Cdc6 depletion abrogates S phase arrest caused by CDDP, leading to aberrant mitosis by inactivating ATR-Chk1-Cdc25C pathway. Our results indicate that Cdc6 may be a promising target for overcoming CDDP resistance in bladder cancer.

SUBMITTER: Chen S 

PROVIDER: S-EPMC5130013 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells.

Chen Sansan S   Chen Xinglu X   Xie Gui'e G   He Yue Y   Yan Daoyu D   Zheng Dianpeng D   Li Shi S   Fu Xinyang X   Li Yeping Y   Pang Xiang X   Hu Zhiming Z   Li Hongwei H   Tan Wanlong W   Li Jinlong J  

Oncotarget 20160601 26

High activation of DNA damage response is implicated in cisplatin (CDDP) resistance which presents as a serious obstacle for bladder cancer treatment. Cdc6 plays an important role in the malignant progression of tumor. Here, we reported that Cdc6 expression is up-regulated in bladder cancer tissues and is positively correlated to high tumor grade. Cdc6 depletion can attenuate the malignant properties of bladder cancer cells, including DNA replication, migration and invasion. Furthermore, higher  ...[more]

Similar Datasets

Unknown DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
| S-EPMC7474466 | biostudies-literature
Unknown ATF2 loss promotes 5-FU resistance in colon cancer cells via activation of the ATR-Chk1 damage response pathway.
| S-EPMC10223906 | biostudies-literature
Unknown Activation of ATR-Chk1 pathway facilitates EBV-mediated transformation of primary tonsillar B-cells.
| S-EPMC5351645 | biostudies-literature
Unknown ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer.
| S-EPMC4811508 | biostudies-literature
Unknown Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer.
| S-EPMC7949146 | biostudies-literature
Unknown Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
| S-EPMC5349188 | biostudies-literature
Unknown CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.
| S-EPMC8414676 | biostudies-literature
Unknown SPHK1 contributes to cisplatin resistance in bladder cancer cells via the NONO/STAT3 axis.
| S-EPMC8480383 | biostudies-literature
Unknown Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells.
| S-EPMC5591524 | biostudies-literature
Unknown Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity.
| S-EPMC4268153 | biostudies-literature